SMTL ID : 5tq5.1

Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.30 Å

Oligo State

monomer

Ligands

1 x 7GX: 6-(2-ethyl-4-hydroxyphenyl)-N-(6-methylpyridin-3-yl)-1H-indazole-3-carboxamide(Non-covalent)

7GX.1: 17 residues within 4Å: Chain A: L.21, V.29, A.46, K.48, E.64, L.68, L.93, M.95, E.96, Y.97, L.98, P.99, G.101, L.149, G.159, D.160, F.161 11 PLIP interactions: 11 interactions with chain A Hydrophobic interactions: A:V.29, A:K.48, A:L.93, A:Y.97, A:L.149 Hydrogen bonds: A:E.64, A:E.64, A:E.96, A:L.98, A:L.98, A:F.161

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Jones, P. et al., Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. J. Med. Chem. (2017)

Release Date

2017-01-11

Peptides

Tyrosine-protein kinase JAK2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Tyrosine-protein kinase JAK2

Related Entries With Identical Sequence